

The new frontiers in oncology

Tecentriq 3rd Anniversary - Powerful Tecentriq in First Line

Date: 10/31, Venue:台北萬豪酒店 3F 博覽廳 (UC)

| Time | Topic | Speaker | Moderator |
|---|---|--|-------------------------------|
| 13:30-14:00 | Registration | All | |
| 14:00-14:05 | Opening – A Hope to Cure UC Patients | 吳文正理事長 高醫附醫 | |
| 14:05-14:25 | Cystectomy/Nephroureterectomy and Peri-operative Therapy for Advanced UC: <i>Now to Future</i> | 張延驊醫師 台北榮總 | 馮思中醫師 林口長庚 |
| 14:25-14:45 | Cystectomy/Nephroureterectomy and Peri-operative Therapy for Advanced UC: <i>Case Sharing</i> | 楊晨洸醫師 台中榮總 | 江博暉醫師 高雄長庚 |
| Connect to Powerful Regimen in 1st Line: Who is the Right Patient to Treat? | | | |
| 14:45-15:05 | How to Choose mUC Patients to Be Treated in 1L Immunotherapy with Biomarkers? | 蘇祐立醫師 高雄長庚 | 黃志平醫師 中國附醫 |
| 15:05-15:25 | How to Choose mUC Patients to Be Treated in 1L Immunotherapy Clinically? | 蘇柏榮醫師 林口長庚 | 蔡育傑醫師 臺大醫院 |
| 15:25-15:45 | Panel Discussion | All | |
| 15:45-16:00 | Coffee Break | | |
| 16:00-17:00 | Learning from Clinical Cases/Database - How Do We Incorporate Cystectomy and Immunotherapy for Locally Advanced UC Patients - Reimbursement Application Experience after Renal Criteria Relaxation - Treatment Considerations for Synchronous UTUC and UBUC (CIS) - Role of Biomarkers in Daily Clinical Practice | 黃子豪醫師 台北榮總 陳柏華醫師 彰基 郭威廷醫師 高雄榮總 郭哲銓醫師 臺大醫院 | 歐宴泉醫師 童綜合 張牧新醫師 台北榮總 |
| 17:00-17:20 | Coffee Break | | |
| Venue:5F 萬豪 II | | | |
| 17:20-18:00 | Tecentriq Avengers Assemble: Transforming the IMpossible into Clinical Possible | Chairman: 張明志醫師/馬偕醫院 張文震醫師 林口長庚 余忠仁醫師 臺大醫院 吳文正醫師 高醫附醫 曾令民醫師 台北榮總 鄭安理醫師 臺大醫院 | |
| 18:00-20:00 | Celebration and Dinner | All | |

The new frontiers in oncology

| Tecentriq 3rd Anniversary - Powerful Tecentriq in First Line | | | |
|---|---|---|----------------|
| Date: 10/31, Venue:台北萬豪酒店 3F 博覽廳 (LC) | | | |
| Time | Topic | Speaker | Moderator |
| 13:30-14:00 | Registration | All | |
| Session I: Connect to Powerful Regimen in 1st Line: Who is the Right Patient to Treat? | | | |
| 14:00-14:10 | Opening | 林孟志醫師 高雄長庚 | |
| 14:10-14:30 | PD-L1 Testing in Non-small Cell Lung Cancer: Annual Analysis by Taipei Institute of Pathology (20 mins lecture) | 王業翰醫師 | 夏德椿醫師 中國附醫 |
| 14:30-15:00 | Clinical Experience Sharing of 1L Anti-VEGF and Anti-PD-L1 Combinational Therapy in Taiwan for Patients with Aggressive Diseases (30 mins lecture) | 張基晟 醫師 中山附醫 | 余忠仁醫師 臺大醫院 |
| 15:00-16:00 | Case by Case Deep Dive into the Management of NSCLC/SCLC and the Use of Atezolizumab | Case Presentation: 王金洲醫師 高雄長庚 黃俊耀醫師 台北慈濟 張時杰醫師 陽大附醫 徐偉勛醫師 臺大醫院 | 楊政達醫師 長庚醫院 |
| 16:00-16:10 | Coffee Break | | |
| Session II: Optimizing Cancer Immunotherapy: Beyond the Present | | | |
| 16:10-16:40 | Existing and Emerging Biomarkers for Cancer Immunotherapy in NSCLC and SCLC (30 mins lecture) | 蔡俊明 醫師 台北榮總 | 余忠仁 醫師 臺大醫院 |
| 16:40-17:10 | Defining Optimal Patient Population for Monotherapy and Combinational Use of Cancer Immunotherapy (30 mins lecture) | 廖唯昱醫師 臺大醫院 | 施金元醫師 臺大醫院 |
| 17:10-17:20 | LC Closing and Transition | 余忠仁 醫師 臺大醫院 | |
| Venue:5F 萬豪 II | | | |
| 17:20-18:00 | Tecentriq Avengers Assemble: Transforming the IMpossible into Clinical Possible | Chairman: 張明志醫師/馬偕醫院 LC: 余忠仁醫師 臺大醫院 UC: 吳文正醫師 高醫附醫 BC: 曾令民醫師 台北榮總 HCC: 鄭安理醫師 臺大醫院 | |
| 18:00-20:00 | Celebration and Dinner | All | |

The new frontiers in oncology

| Tecentriq 3rd Anniversary - Powerful Tecentriq in First Line | | | |
|---|--|---|----------------|
| Date: 10/31, Venue:台北萬豪酒店 3F 春夏秋冬廳 (BC) | | | |
| Time | Topic | Speaker | Moderator |
| 13:30-14:00 | Registration | All | |
| Connect to Powerful Regimen in 1st Line: Who is the Right Patient to Treat? | | | |
| 14:00-14:10 | Opening – A New Hope for TNBC Patient | 曾令民理事長 乳房醫學會 | |
| 14:10-14:20 | Roadmap for the Treatment of Metastatic Triple Negative Breast Cancer | 俞志誠教授 三軍總醫院 | |
| 14:20-14:35 | Evolving Immunotherapy Combination Strategies in 1L mTNBC - Key Evidence and Remaining Questions for Clinical Application of Immunotherapy | 陳偉武醫師 臺大醫院 | 黃俊升教授 臺大醫院 |
| 14:35-14:50 | Balancing Efficacy and Safety in Treatment with Cancer Immunotherapy | 戴明燊主任 三軍總醫院 | 沈陳石銘教授 北醫附醫 |
| 14:50-15:15 | Voting & Discussion | All Experts | 黃俊升醫師 |
| 15:15-15:30 | Coffee Break | | |
| 15:30-15:40 | Turn Negative to Positive - What Can We Learn from PD-L1 Testing and Genetic Information of Breast Cancers? – VGH Experiences | 趙大中醫師 台北榮總 | 葉大成醫療長 中港澄清 |
| 15:40-15:50 | - What is the Difference of Clinical Consideration When Applying Immunotherapy in Inoperable Locally Advanced and Metastatic Breast Cancer Patients? – CGMH Experiences | 沈士哲醫師 林口長庚 | 陳訓徹教授 林口長庚 |
| 15:50-16:00 | - How to Enhance Effect of Immunotherapy in TNBC Patients? – CMUH Experiences | 劉良智主任 中國附醫 | 陳達人教授 彰基 |
| 16:00-16:10 | - When to Resume Immunotherapy Following an Immune-related Adverse Event? – VGHTC Experiences | 洪志強主任 台中榮總 | 張金堅教授 臺大醫院 |
| 16:10-16:20 | - Is PD-L1 a Valid Biomarker for 1L Immunotherapy? – KMUH Experiences | 莊捷翰主任 高雄附醫 | 侯明鋒教授 高醫附院 |
| 16:20-16:50 | Experts Discussion for Clinical Challenging Cases | All Experts | 陳訓徹教授 林口長庚 |
| 16:50-17:00 | Closing | 曾令民理事長 乳房醫學會 | |
| 17:00-17:20 | Coffee Break | | |
| Venue:5F 萬豪 II | | | |
| 17:20-18:00 | Tecentriq Avengers Assemble: Transforming the IMpossible into Clinical Possible | Chairman: 張明志醫師/馬偕醫院 LC: 余忠仁醫師 臺大醫院 UC: 吳文正醫師 高醫附醫 BC: 曾令民醫師 台北榮總 HCC: 鄭安理醫師 臺大醫院 | |
| 18:00-20:00 | Celebration and Dinner | All | |

The new frontiers in oncology

| Tecentriq 3rd Anniversary - Powerful Tecentriq in First Line | | | |
|---|---|---|-----------------------|
| Date: 10/31, Venue:台北萬豪酒店 3F 博覽廳 (HCC) | | | |
| Time | Topic | Speaker | Moderator |
| 13:30-14:00 | Registration | All | |
| 14:00-14:05 | Opening | 林錫銘醫師 林口長庚 | |
| Connect to Powerful Regimen in 1st Line: Who is the Right Patient to Treat? | | | |
| 14:05-14:25 | Making the Correct Clinical Decisions for Advanced HCC: What Do We Need to Know When Treating HCC Patients? | 戴嘉言醫師 高醫附醫 | 余明隆醫師 高醫附醫 |
| 14:25-14:45 | Impact of IMbrave150 on the Advanced HCC Treatment Landscape | 邵幼雲醫師 臺大醫院 | 徐志宏醫師 臺大醫院 |
| 14:45-15:05 | Surgical Resection and Liver Transplantation for HCC | 李威震醫師 林口長庚(TBD) | 沈延盛醫師 成大醫院 (TBD) |
| 15:05-15:25 | Panel Discussion | All | |
| 15:25-15:40 | Coffee Break | | |
| Integrating Cancer Immunotherapy Combinations into HCC Treatment | | | |
| 15:40-16:00 | Expert Clinical Experience: Tecentriq + Avastin Combination in Patients with HCC | 謝彝中醫師 林口長庚 | 楊勝舜醫師 台中榮總 |
| 16:00-16:20 | Expert Clinical Experience: Tecentriq + Avastin Combination in Patients with HCC | TBD | 賴學洲醫師 中國附醫 |
| 16:20-16:40 | Expert Clinical Experience: Tecentriq + Avastin Combination in Patients with HCC | 顏家瑞醫師 成大醫院 | 陳冠仰 北市聯仁愛 (TBD) |
| 17:00-17:20 | Coffee Break | | |
| Venue:5F 萬豪 II | | | |
| 17:20-18:00 | Tecentriq Avengers Assemble: Transforming the IMpossible into Clinical Possible | Chairman: 張明志醫師/馬偕醫院 LC: 余忠仁醫師 臺大醫院 UC: 吳文正醫師 高醫附醫 BC: 曾令民醫師 台北榮總 HCC: 鄭安理醫師 臺大醫院 | |
| 18:00-20:00 | Celebration and Dinner | All | |

The new frontiers in oncology

| Innovative development of therapeutics and biomarkers to optimize cancer management (Breast cancer) | | | |
|---|--|--|--------------------|
| Date: 11/1, Venue:台北萬豪酒店 3F 秋冬廳 | | | |
| Time | Topic | Speaker | Moderator |
| 9:00-9:50* | Opening & Oncology pipeline strategy: a snapshot at Roche | Dr. Edward Cha Global Development Lead, Roche-Genentech | 許駿 主委 中華民國癌症醫學會 |
| Break out | | | |
| 9:55-10:00 | Opening | 曾令民 理事長 台灣乳房醫學會 | |
| 10:00-11:00 | Recent advances of immunotherapy in early TNBC | 郭玟伶 醫師 林口長庚醫院 | 陳訓徹 教授 林口長庚醫院 |
| 11:00-11:40 | Recent treatment advances and future perspectives in HER2+ Breast Cancer | 鍾為邦 醫師 成大醫院 | 王惠暢 顧問 中國附醫 |
| 11:40-12:15 | Recent treatment advances and future perspectives in HR+ Breast Cancer | 陳守棟 醫師 彰化基督教醫院 | 曾令民 理事長 台灣乳房醫學會 |
| 12:15-12:20 | Closing | 曾令民 理事長 台灣乳房醫學會 | |

*視訊形式

座位有限，需線上報名，報名網址：<https://reurl.cc/gmabK4>

The new frontiers in oncology

| Innovative development of therapeutics and biomarkers to optimize cancer management (Lung cancer) | | | |
|---|---|---|------------------------|
| Date: 11/1, Venue: 台北萬豪酒店 3F 春夏廳 | | | |
| Time | Topic | Speaker | Moderator |
| 9:00-9:50* | Opening & Oncology pipeline strategy: a snapshot at Roche | Dr. Edward Cha Global Development Lead, Roche-Genentech | 許駿 主委 中華民國癌症醫學 會 |
| Break out | | | |
| 09:50-09:55 | Opening | 余忠仁 教授 台大醫院 | |
| 09:55-10:15 | Recent advances in early stage NSCLC | 李岡遠 教授 雙和醫院 | 許瀚水 教授 台北榮總 |
| 10:15-10:40 | How to optimize immune-based treatment outcome: existing and emerging evidence- Overview 2020 update | 施金元 教授 台大醫院 | 蔡俊明 教授 台北榮總 |
| 10:40-10:55 | Coffee break | | |
| 10:55-11:20* | Innovation in cancer management - Discovery in pipeline and evolution in biomarker strategy | Dr. Raymond Meng, Global Development Lead, Roche-Genentech | 余忠仁 教授 台大醫院 |
| 11:20-11:45* | How to optimize patient selection and outcome based on biomarker strategy: what is known and what is under developments | Prof. Myung-Ju Ahn, Samsung Medical Center, Korea | 楊志新 教授 台大醫院 |
| 11:45-12:25 | Panel Discussion & Interactive QA: Current Challenges and Future Perspective | Panelist | 楊志新 教授 台大醫院 |
| 12:25-12:30 | Closing | 楊志新 教授 台大醫院 | |

*視訊形式

座位有限，需線上報名，報名網址：<https://reurl.cc/gmabK4>

The new frontiers in oncology

| Innovative development of therapeutics and biomarkers to optimize cancer management (Urothelial cancer) | | | |
|---|--|---|--------------------|
| Date: 11/1, Venue: 台北萬豪酒店 5F 宜華二廳 | | | |
| Time | Topic | Speaker | Moderator |
| 9:00-9:50* | Opening & Oncology pipeline strategy: a snapshot at Roche | Dr. Edward Cha Global Development Lead, Roche-Genentech | 許駿 主委 中華民國癌症醫學會 |
| Break out | | | |
| 9:50-9:55 | Reshaping GU treatment paradigms | 吳文正 理事長 台灣泌尿科醫學會 | |
| 9:55-10:45 | 1L mUC combinations: lessons from clinical trials to real world experience | 蔡育賢 教授 成大醫院 & 李建儀 副教授 台中榮總 | 查岱龍 校長 國防醫學院 |
| 10:45-11:20 | Neoadjuvant for MIBC: chemotherapy or checkpoint inhibition? | 薛富仁 醫師 台大醫院 & 魏子鈞 醫師 台北榮總 | 余家政 部長 高雄榮總 |
| 11:20-11:45 | Advancing mCRPC treatment with ipatasertib – a new PI3K/AKT inhibitor | 王賢祥 主任 台中榮總 | 蒲永孝 教授 台大醫院 |
| 11:45-12:00 | Panel discussion & closing | All | 蒲永孝 教授 台大醫院 |

*視訊形式

座位有限，需線上報名，報名網址：<https://reurl.cc/gmabK4>

The new frontiers in oncology

| Innovative development of therapeutics and biomarkers to optimize cancer management (GI cancer) | | | |
|---|---|--|--------------------|
| Date: 11/1, Venue: 台北萬豪酒店 5F 宜華一廳 | | | |
| Time | Topic | Speaker | Moderator |
| 9:00-9:50* | Opening & Oncology pipeline strategy: a snapshot at Roche | Dr. Edward Cha Global Development Lead, Roche-Genentech | 許駿 主委 中華民國癌症醫學會 |
| Break out | | | |
| 9:50-10:00 | Opening | 許駿 主委 中華民國癌症醫學會 | |
| 10:00-10:30 | One liver story - from diagnosis to treatment | 林成俊 醫師 林口長庚醫院 | 許朝偉 主任 林口長庚醫院 |
| 10:30-11:00 | Frontier in GI cancers - The ongoing development plan across tumor types and stages | 顏家瑞 教授 成大醫院 | 饒坤銘 副院長 義大醫院 |
| 11:00-11:10 | Coffee break | | |
| 11:10-11:40 | Biomarkers – challenges and opportunities to optimize HCC treatment | 沈盈君 醫師 臺大癌醫中心 | 鄭安理 教授 台大醫院 |
| 11:40-11:55 | Panel discussion | All | 鄭安理 教授 台大醫院 |
| 11:55-12:00 | Closing | 鄭安理 教授 台大醫院 | |

*視訊形式

座位有限，需線上報名，報名網址：<https://reurl.cc/gmabK4>